YMAB
Y-mAbs Therapeutics, Inc.
YMAB
(1.5)14,00 USD
-15.49% ROA
-19.47% ROE
-18.72x PER
365.985.224,00 USD
1.62% DER
0% Yield
-23.74% NPM
Y-mAbs Therapeutics, Inc. Stock Analysis
Y-mAbs Therapeutics, Inc. Fundamental Analysis
Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.
| # | Analysis | Rating |
|---|---|---|
| 1 |
DER
The stock has a low debt to equity ratio (1%), which means it has a small amount of debt compared to the ownership it holds |
|
| 2 |
Revenue Growth
With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity. |
|
| 3 |
PBV
The stock's PBV ratio (2.26x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns. |
|
| 4 |
Graham Number
The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity. |
|
| 5 |
ROE
Negative ROE (-38.02%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity. |
|
| 6 |
ROA
The stock's ROA (-31.51%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns. |
|
| 7 |
Net Profit Growth
This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity. |
|
| 8 |
Assets Growth
Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice. |
|
| 9 |
Dividend Growth
The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns. |
|
| 10 |
Dividend
The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns. |
|
| 11 |
Buffet Intrinsic Value
The company's stock presents a potential concern as it appears overvalued (-10) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value. |
Y-mAbs Therapeutics, Inc. Technical Analysis
Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.
| # | Analysis | Recommendation |
|---|---|---|
| 1 | Awesome Oscillator | Sell |
| 2 | MACD | Buy |
| 3 | RSI | Hold |
| 4 | Stoch RSI | Sell |
Y-mAbs Therapeutics, Inc. Price Chart
Financial Statements
Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.
Income Statements
An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.
Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.
| Year | Revenue | Growth |
|---|---|---|
| 2016 | 0 | |
| 2017 | 0 | 0% |
| 2018 | 0 | 0% |
| 2019 | 0 | 0% |
| 2020 | 20.750.000 | 100% |
| 2021 | 34.897.000 | 40.54% |
| 2022 | 65.267.000 | 46.53% |
| 2023 | 81.816.000 | 20.23% |
Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.
| Year | Research and Development Expenses | Growth |
|---|---|---|
| 2016 | 13.855.000 | |
| 2017 | 14.307.000 | 3.16% |
| 2018 | 34.269.000 | 58.25% |
| 2019 | 63.492.000 | 46.03% |
| 2020 | 93.697.000 | 32.24% |
| 2021 | 93.245.000 | -0.48% |
| 2022 | 91.572.000 | -1.83% |
| 2023 | 61.432.000 | -49.06% |
General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.
| Year | General and Administrative Expenses | Growth |
|---|---|---|
| 2016 | 3.184.000 | |
| 2017 | 4.937.000 | 35.51% |
| 2018 | 8.961.000 | 44.91% |
| 2019 | 19.512.000 | 54.07% |
| 2020 | 44.785.000 | 56.43% |
| 2021 | 0 | 0% |
| 2022 | 0 | 0% |
| 2023 | 0 | 0% |
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.
| Year | EBITDA | Growth |
|---|---|---|
| 2016 | -17.039.000 | |
| 2017 | -19.244.000 | 11.46% |
| 2018 | -43.230.000 | 55.48% |
| 2019 | -83.004.000 | 47.92% |
| 2020 | -117.732.000 | 29.5% |
| 2021 | -115.433.000 | -1.99% |
| 2022 | -94.811.000 | -21.75% |
| 2023 | -30.996.000 | -205.88% |
Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.
| Year | Gross Profit | Growth |
|---|---|---|
| 2016 | 0 | |
| 2017 | 0 | 0% |
| 2018 | 0 | 0% |
| 2019 | 0 | 0% |
| 2020 | 18.547.000 | 100% |
| 2021 | 32.383.000 | 42.73% |
| 2022 | 57.700.000 | 43.88% |
| 2023 | 71.236.000 | 19% |
Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.
| Year | Net Profit | Growth |
|---|---|---|
| 2016 | -17.057.000 | |
| 2017 | -19.161.000 | 10.98% |
| 2018 | -43.274.000 | 55.72% |
| 2019 | -78.886.000 | 45.14% |
| 2020 | -118.343.000 | 33.34% |
| 2021 | -56.345.000 | -110.03% |
| 2022 | -96.325.000 | 41.51% |
| 2023 | -30.988.000 | -210.85% |
EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.
| Year | Earning per Share (EPS) | Growth |
|---|---|---|
| 2016 | -1 | |
| 2017 | -1 | 0% |
| 2018 | -2 | 100% |
| 2019 | -2 | 50% |
| 2020 | -3 | 0% |
| 2021 | -1 | -100% |
| 2022 | -2 | 50% |
| 2023 | -1 | 0% |
Cashflow Statements
Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.
Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.
| Year | Free Cashflow | Growth |
|---|---|---|
| 2016 | -11.166.000 | |
| 2017 | -15.870.000 | 29.64% |
| 2018 | -41.463.000 | 61.72% |
| 2019 | -75.462.000 | 45.05% |
| 2020 | -91.406.000 | 17.44% |
| 2021 | -103.523.000 | 11.7% |
| 2022 | -75.921.000 | -36.36% |
| 2023 | -1.338.000 | -5574.22% |
Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.
| Year | Operating Cashflow | Growth |
|---|---|---|
| 2016 | -11.166.000 | |
| 2017 | -15.870.000 | 29.64% |
| 2018 | -41.229.000 | 61.51% |
| 2019 | -73.497.000 | 43.9% |
| 2020 | -91.231.000 | 19.44% |
| 2021 | -102.556.000 | 11.04% |
| 2022 | -75.921.000 | -35.08% |
| 2023 | -1.338.000 | -5574.22% |
Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.
| Year | Capital Expenditure | Growth |
|---|---|---|
| 2016 | 0 | |
| 2017 | 0 | 0% |
| 2018 | 234.000 | 100% |
| 2019 | 1.965.000 | 88.09% |
| 2020 | 175.000 | -1022.86% |
| 2021 | 967.000 | 81.9% |
| 2022 | 0 | 0% |
| 2023 | 0 | 0% |
Balance Sheet
Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.
Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.
| Year | Equity | Growth |
|---|---|---|
| 2016 | 12.061.000 | |
| 2017 | 82.152.000 | 85.32% |
| 2018 | 140.527.000 | 41.54% |
| 2019 | 198.903.000 | 29.35% |
| 2020 | 105.836.000 | -87.94% |
| 2021 | 180.106.000 | 41.24% |
| 2022 | 109.221.000 | -64.9% |
| 2023 | 100.150.000 | -9.06% |
Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.
| Year | Assets | Growth |
|---|---|---|
| 2016 | 17.261.000 | |
| 2017 | 92.127.000 | 81.26% |
| 2018 | 151.924.000 | 39.36% |
| 2019 | 216.366.000 | 29.78% |
| 2020 | 132.047.000 | -63.86% |
| 2021 | 212.783.000 | 37.94% |
| 2022 | 141.456.000 | -50.42% |
| 2023 | 128.884.000 | -9.75% |
Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.
| Year | Liabilities | Growth |
|---|---|---|
| 2016 | 5.200.000 | |
| 2017 | 9.975.000 | 47.87% |
| 2018 | 11.397.000 | 12.48% |
| 2019 | 17.463.000 | 34.74% |
| 2020 | 26.211.000 | 33.38% |
| 2021 | 32.677.000 | 19.79% |
| 2022 | 32.235.000 | -1.37% |
| 2023 | 28.734.000 | -12.18% |
Y-mAbs Therapeutics, Inc. Financial Ratio (TTM)
Valuation Metrics
- Revenue per Share
- 2.13
- Net Income per Share
- -0.45
- Price to Earning Ratio
- -18.72x
- Price To Sales Ratio
- 3.94x
- POCF Ratio
- -13.14
- PFCF Ratio
- -13.14
- Price to Book Ratio
- 3.65
- EV to Sales
- 3.03
- EV Over EBITDA
- -11.9
- EV to Operating CashFlow
- -10.09
- EV to FreeCashFlow
- -10.09
- Earnings Yield
- -0.05
- FreeCashFlow Yield
- -0.08
- Market Cap
- 0,37 Bil.
- Enterprise Value
- 0,28 Bil.
- Graham Number
- 4.81
- Graham NetNet
- 1.73
Income Statement Metrics
- Net Income per Share
- -0.45
- Income Quality
- 1.44
- ROE
- -0.19
- Return On Assets
- -0.16
- Return On Capital Employed
- -0.24
- Net Income per EBT
- 0.96
- EBT Per Ebit
- 0.81
- Ebit per Revenue
- -0.3
- Effective Tax Rate
- 0.04
Margins
- Sales, General, & Administrative to Revenue
- 0
- Research & Developement to Revenue
- 0.65
- Stock Based Compensation to Revenue
- 0.16
- Gross Profit Margin
- 0.87
- Operating Profit Margin
- -0.3
- Pretax Profit Margin
- -0.25
- Net Profit Margin
- -0.24
Dividends
- Dividend Yield
- 0
- Dividend Yield %
- 0
- Payout Ratio
- 0
- Dividend Per Share
- 0
Operating Metrics
- Operating Cashflow per Share
- -0.64
- Free CashFlow per Share
- -0.64
- Capex to Operating CashFlow
- 0
- Capex to Revenue
- 0
- Capex to Depreciation
- 0
- Return on Invested Capital
- -0.24
- Return on Tangible Assets
- -0.15
- Days Sales Outstanding
- 74.15
- Days Payables Outstanding
- 243.72
- Days of Inventory on Hand
- 227.8
- Receivables Turnover
- 4.92
- Payables Turnover
- 1.5
- Inventory Turnover
- 1.6
- Capex per Share
- 0
Balance Sheet
- Cash per Share
- 1,98
- Book Value per Share
- 2,30
- Tangible Book Value per Share
- 2.23
- Shareholders Equity per Share
- 2.3
- Interest Debt per Share
- -0.05
- Debt to Equity
- 0.02
- Debt to Assets
- 0.01
- Net Debt to EBITDA
- 3.6
- Current Ratio
- 5.27
- Tangible Asset Value
- 0,10 Bil.
- Net Current Asset Value
- 0,09 Bil.
- Invested Capital
- 0.02
- Working Capital
- 0,09 Bil.
- Intangibles to Total Assets
- 0.02
- Average Receivables
- 0,02 Bil.
- Average Payables
- 0,01 Bil.
- Average Inventory
- 6150000
- Debt to Market Cap
- 0
Dividends
Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.
| Year | Dividends | Growth |
|---|
Y-mAbs Therapeutics, Inc. Profile
About Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
- CEO
- Mr. Michael Rossi
- Employee
- 100
- Address
-
230 Park Avenue
New York, 10169
Y-mAbs Therapeutics, Inc. Executives & BODs
| # | Name | Age |
|---|---|---|
| 1 |
Mr. Thomas Gad Founder, Chief Business Officer & Vice Chairman |
70 |
| 2 |
Ms. Courtney Dugan Vice President of Investor Relations |
70 |
| 3 |
Dr. Steen Lisby M.D., M.Sc. Senior Vice President & Chief Scientific Officer |
70 |
| 4 |
Dr. Vignesh Rajah M.B.A., MBBS Senior Vice President & Chief Medical Officer |
70 |
| 5 |
Mr. Michael Rossi Chief Executive Officer, President & Director |
70 |
| 6 |
Dr. Torben Lund-Hansen M.Sc., Ph.D. Senior Vice President & Chief Technology Officer |
70 |
| 7 |
Mr. Bo Kruse Executive Vice President, Secretary, Treasurer & Chief Financial Officer |
70 |
| 8 |
Ms. Susan Smith Senior Vice President & Chief Commercial Officer |
70 |
| 9 |
Mr. Joris Wiel Jan Wilms Senior Vice President & Chief Operating Officer |
70 |
Y-mAbs Therapeutics, Inc. Competitors
